AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34261992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex, age, and BMI associations
Number of subjects: 2195
Study 33196605 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g KE
Number of subjects: 14
Study 33196605 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg·kg‐1 body weight NaHCO3 (BIC)
Number of subjects: 14
Study 33196605 — intervention group
Group type: EXPERIMENTAL
Intervention: KE + BIC
Number of subjects: 14
Study 33196605 — intervention group
Group type: COMPARATOR
Intervention: Control drink (CON)
Number of subjects: 14
Study 34509641 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume split-dose PEG (2 L + 2 L)
Number of subjects: 2314
Study 34509641 — intervention group
Group type: COMPARATOR
Intervention: Low-volume split-dose PEG (1 L + 1 L) + bisacodyl (15 mg)
Number of subjects: 2314
Study 32012284 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate light source (ALS) at 415 nm using a yellow filter
Number of subjects: 157
Study 32012284 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate light source (ALS) at 450 nm using a yellow filter
Number of subjects: 157
Study 32012284 — intervention group
Group type: COMPARATOR
Intervention: White light
Number of subjects: 157
Study 32012284 — intervention group
Group type: EXPERIMENTAL
Intervention: Female participants
Number of subjects: 157
Study 32012284 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized fat
Number of subjects: 157
Study 36445213 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-mm bulb obturator (G1)
Number of subjects: 17
Study 36445213 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mm bulb obturator (G2)
Number of subjects: 17
Study 36445213 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mm bulb obturator (G3)
Number of subjects: 17
Study 36445213 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight of obturators
Number of subjects: 17
Study 34036357 — intervention group
Group type: COMPARATOR
Intervention: Calorie-free control (water)
Number of subjects: 58
Study 34036357 — intervention group
Group type: EXPERIMENTAL
Intervention: Skim milk
Number of subjects: 58
Study 34036357 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk
Number of subjects: 58
Study 34036357 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 g Greek yogurt
Number of subjects: 58
Study 34036357 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 g cheddar cheese
Number of subjects: 58
Study 34036357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy products (overall)
Number of subjects: 58
Study 34252178 — intervention group
Group type: EXPERIMENTAL
Intervention: 5A's counselling administered by nurses
Number of subjects: 480
Study 34252178 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 480
Study 33476537 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of paeony (TGP) treatment group
Number of subjects: 64
Study 33476537 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment group
Number of subjects: 64
Study 32938433 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin to skin contact
Number of subjects: 28121
Study 32938433 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of breastfeeding
Number of subjects: 28121
Study 32938433 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of one element
Number of subjects: 28121
Study 32938433 — intervention group
Group type: EXPERIMENTAL
Intervention: Receipt of all four elements
Number of subjects: 28121
Study 32812478 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE), manual therapy (MT), and home exercise program (HEP)
Number of subjects: 69
Study 32812478 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) and home exercise program (HEP)
Number of subjects: 69
Study 32812478 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program (HEP)
Number of subjects: 69
Study 32030863 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 32030863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36330870 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms message and outcome expectancy message
Number of subjects: 475
Study 36330870 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk reduction message and response efficacy message
Number of subjects: 475
Study 36330870 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort acknowledgement message and support message
Number of subjects: 475
Study 36330870 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple messages combined
Number of subjects: 475
Study 36330870 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic information about cervical screening)
Number of subjects: 475
Study 32088198 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing a head‐mounted eye tracker
Number of subjects: 25
Study 32088198 — intervention group
Group type: COMPARATOR
Intervention: Eyes closed
Number of subjects: 25
Study 32088198 — intervention group
Group type: COMPARATOR
Intervention: Horizontal saccades
Number of subjects: 25
Study 36028729 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief perceptual training (n=15)
Number of subjects: 30
Study 36028729 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=15)
Number of subjects: 30
Study 36028729 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief perceptual training
Number of subjects: 30
Study 34362762 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic oxygen titration using a novel nasal high-flow device
Number of subjects: 20
Study 34362762 — intervention group
Group type: COMPARATOR
Intervention: Manual oxygen titration using nasal high flow
Number of subjects: 20
Study 34362762 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic oxygen titration
Number of subjects: 20
Study 32539853 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of pan-genotypic DAA treatment with individualized follow-up
Number of subjects: 220
Study 32539853 — intervention group
Group type: COMPARATOR
Intervention: Standard of care: referral to outpatient care at discharge
Number of subjects: 220
Study 35778977 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB008 (infliximab biosimilar)
Number of subjects: 90
Study 35778977 — intervention group
Group type: COMPARATOR
Intervention: Infliximab reference product (Remicade)
Number of subjects: 90
Study 35778977 — intervention group
Group type: EXPERIMENTAL
Intervention: CMAB008
Number of subjects: 90
Study 35778977 — intervention group
Group type: COMPARATOR
Intervention: Infliximab reference product
Number of subjects: 90
Study 34932079 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids (1 g/d of fish oil, including 465 mg of eicosapentaenoic acid and 375 mg of docosahexaenoic acid)
Number of subjects: 18353
Study 34932079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18353
Study 34932079 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids (1 g/d of fish oil)
Number of subjects: 18353
Study 34932079 — intervention group
Group type: EXPERIMENTAL
Intervention: Marine omega-3 fatty acids
Number of subjects: 18353
Study 36266551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS) based on race, histological type, tumor grade, T stage, N stage, carcinoembryonic antigen (CEA) level, and number of lymph nodes (LN) examined.
Number of subjects: 3026
Study 36266551 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 3026
Study 34779063 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 0
Study 34779063 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 0
Study 34779063 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg
Number of subjects: 0
Study 34779063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34393178 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-assisted PRK
Number of subjects: 82
Study 34393178 — intervention group
Group type: COMPARATOR
Intervention: Mechanical PRK
Number of subjects: 82
Study 34393178 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 35586670 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-approach laparoscopic splenectomy
Number of subjects: 62
Study 35586670 — intervention group
Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 62
Study 33859330 — intervention group
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS) prebiotic supplement
Number of subjects: 64
Study 33859330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 32613727 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 1413
Study 32613727 — intervention group
Group type: COMPARATOR
Intervention: Type 1 diabetes
Number of subjects: 1413
Study 35580487 — intervention group
Group type: EXPERIMENTAL
Intervention: DRY group cycling at 125‐150W for one hour in a non‐immersed condition (34.4˚C, 50%RH)
Number of subjects: 19
Study 35580487 — intervention group
Group type: EXPERIMENTAL
Intervention: WET group cycling at 50W for one hour while immersed in 34.4˚C water
Number of subjects: 19
Study 35580487 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HOT vs WARM water
Number of subjects: 19
Study 35580487 — intervention group
Group type: COMPARATOR
Intervention: Rate of Tc rise
Number of subjects: 19
Study 35580487 — intervention group
Group type: COMPARATOR
Intervention: Maximum Tc and Tc change from baseline
Number of subjects: 19
Study 35848700 — intervention group
Group type: EXPERIMENTAL
Intervention: P. oleracea
Number of subjects: 60
Study 35848700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32956797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tack Endovascular System
Number of subjects: 233
Study 36440618 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillomate 9002
Number of subjects: 82
Study 36440618 — intervention group
Group type: COMPARATOR
Intervention: Mindray VS‐900
Number of subjects: 82
Study 33534909 — intervention group
Group type: EXPERIMENTAL
Intervention: B. sessilis (faster growing)
Number of subjects: 2
Study 33534909 — intervention group
Group type: COMPARATOR
Intervention: B. attenuata (slower growing)
Number of subjects: 2
Study 33534909 — intervention group
Group type: EXPERIMENTAL
Intervention: Both species
Number of subjects: 2
Study 33534909 — intervention group
Group type: EXPERIMENTAL
Intervention: B. sessilis
Number of subjects: 2
Study 32341247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) at 250 mm Hg; four 5-minute cycles of ischemia
Number of subjects: 14
Study 32341247 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment at 20 mm Hg
Number of subjects: 14
Study 33956130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg biweekly)
Number of subjects: 487
Study 33956130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (fixed dose of 240 mg biweekly or 480 mg monthly)
Number of subjects: 487
Study 33956130 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 487
Study 33158451 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoints on the Heart Meridian
Number of subjects: 148
Study 33158451 — intervention group
Group type: COMPARATOR
Intervention: Acupoints on the Lung Meridian
Number of subjects: 148
Study 34417369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Collard (MC) technique
Number of subjects: 100
Study 34417369 — intervention group
Group type: COMPARATOR
Intervention: Circular Stapled (CS) technique
Number of subjects: 100
Study 34215210 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 501
Study 34215210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 501
Study 32769818 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive whole-body bio-impedance technology (NiCAS) during phlebotomy
Number of subjects: 80
Study 32769818 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 35716058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled radiofrequency ablation (CRFA) of genicular nerves
Number of subjects: 36
Study 32293334 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week high intensity interval training (HIIT) programme
Number of subjects: 78
Study 32293334 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative care
Number of subjects: 78
Study 36460959 — intervention group
Group type: EXPERIMENTAL
Intervention: Salutogenic Healthy Ageing Programme Embracement (SHAPE) intervention
Number of subjects: 34
Study 36460959 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 34
Study 33383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + ciprofloxacin
Number of subjects: 66
Study 33383182 — intervention group
Group type: COMPARATOR
Intervention: Ca(OH)2
Number of subjects: 66
Study 33383182 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca(OH)2 + ibuprofen
Number of subjects: 66
Study 35592857 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg pregabalin
Number of subjects: 75
Study 35592857 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pregabalin
Number of subjects: 75
Study 35592857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 33243815 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP256V2LS administered intravenously
Number of subjects: 0
Study 33243815 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP256V2LS administered subcutaneously with and without rHuPH20
Number of subjects: 0
Study 33243815 — intervention group
Group type: COMPARATOR
Intervention: CAP256V2LS+VRC07-523LS administered SC
Number of subjects: 0
Study 33243815 — intervention group
Group type: COMPARATOR
Intervention: CAP256V2LS+PGT121 administered SC
Number of subjects: 0
Study 33243815 — intervention group
Group type: COMPARATOR
Intervention: CAP256V2LS+VRC07-523LS+PGT121 administered SC
Number of subjects: 0
Study 34988679 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release formulation of posaconazole
Number of subjects: 0
Study 34988679 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologically based pharmacokinetic modeling
Number of subjects: 0
Study 34058717 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (7000 mg/d)
Number of subjects: 10
Study 34058717 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium sodium diet (2300 mg/d)
Number of subjects: 10
Study 34058717 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (1000 mg/d)
Number of subjects: 10
Study 32533985 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer 2-5h after thaw (Group D2)
Number of subjects: 388
Study 32533985 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer 18-24h after thaw (Group D2/D3)
Number of subjects: 388
Study 35543540 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 intradetrusor injections of onabotulinumtoxinA
Number of subjects: 0
Study 35543540 — intervention group
Group type: COMPARATOR
Intervention: 20 intradetrusor injections of onabotulinumtoxinA
Number of subjects: 0
Study 35181532 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1.5 mA for 20 minutes over two consecutive weeks)
Number of subjects: 41
Study 35181532 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 41
Study 32950829 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (30–50 mg·kg−1 intravenously as a bolus before induction, followed by 10–20 mg·kg−1 h−1 continuous infusion during surgery)
Number of subjects: 49
Study 32950829 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 36199107 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 200
Study 36199107 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 200
Study 36199107 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 200
Study 36199107 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WL)
Number of subjects: 200
Study 33750533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 33750533 — intervention group
Group type: COMPARATOR
Intervention: Waiting group
Number of subjects: 0
Study 32564251 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid (PDA)
Number of subjects: 60
Study 32564251 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 35002241 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/d)
Number of subjects: 50
Study 35002241 — intervention group
Group type: COMPARATOR
Intervention: Control (no fluoxetine)
Number of subjects: 50
Study 616351330 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid L‐T4 formulation
Number of subjects: 0
Study 616351330 — intervention group
Group type: COMPARATOR
Intervention: Tablet form L‐T4
Number of subjects: 0
Study 35089948 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 1 of the EEfRT
Number of subjects: 514
Study 35089948 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 2 of the EEfRT
Number of subjects: 514
Study 35089948 — intervention group
Group type: EXPERIMENTAL
Intervention: Original EEfRT
Number of subjects: 514
Study 33556204 — intervention group
Group type: EXPERIMENTAL
Intervention: oXiris
Number of subjects: 20
Study 33556204 — intervention group
Group type: COMPARATOR
Intervention: M150
Number of subjects: 20
Study 36197179 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative walking enhanced by goal setting with an activity monitor and telephonic coaching
Number of subjects: 83
Study 36197179 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 83
Study 33607177 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (Jak1/2 inhibitor), oral treatment for four weeks
Number of subjects: 100
Study 33607177 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 100
Study 32359843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 537
Study 32359843 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 537
Study 32359843 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 537
Study 35393472 — intervention group
Group type: EXPERIMENTAL
Intervention: Damped maskers
Number of subjects: 0
Study 35393472 — intervention group
Group type: COMPARATOR
Intervention: Ramped maskers
Number of subjects: 0
Study 35393472 — intervention group
Group type: EXPERIMENTAL
Intervention: Disconnected sentences
Number of subjects: 0
Study 35393472 — intervention group
Group type: EXPERIMENTAL
Intervention: Stories with randomized sentence order
Number of subjects: 0
Study 35393472 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaging and coherent narrative stories
Number of subjects: 0
Study 34083663 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat‐not‐Burn cigarette (HNBC)
Number of subjects: 75
Study 34083663 — intervention group
Group type: COMPARATOR
Intervention: Tobacco cigarette (Tcig)
Number of subjects: 75
Study 34967496 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVHDF
Number of subjects: 60
Study 34967496 — intervention group
Group type: COMPARATOR
Intervention: CVVH
Number of subjects: 60
Study 33236949 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 32
Study 33236949 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 32
Study 35429309 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation among clients visiting specifically to initiate PrEP
Number of subjects: 1782
Study 35429309 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation among clients visiting for HIV testing
Number of subjects: 1782
Study 35429309 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP initiation among clients visiting for outpatient services
Number of subjects: 1782
Study 35429309 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred delivery settings among those who initiated PrEP
Number of subjects: 1782
Study 32159857 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-CT method
Number of subjects: 60
Study 32159857 — intervention group
Group type: COMPARATOR
Intervention: Radiographic method
Number of subjects: 60
Study 32159857 — intervention group
Group type: COMPARATOR
Intervention: Randomization method
Number of subjects: 60
Study 35060403 — intervention group
Group type: EXPERIMENTAL
Intervention: CSD500
Number of subjects: 500
Study 34080008 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (FCM)
Number of subjects: 1058
Study 34080008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1058
Study 36303868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of white common bean extract (WCBE) taken half an hour before a meal (Group W)
Number of subjects: 90
Study 36303868 — intervention group
Group type: COMPARATOR
Intervention: 1.5 g of maltodextrin as a placebo (Group C)
Number of subjects: 90
Study 36303868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g of white common bean extract (WCBE) (Group W)
Number of subjects: 90
Study 35607722 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider's personal phone number (PPN) group
Number of subjects: 507
Study 35607722 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PPN)
Number of subjects: 507
Study 35607722 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider's PPN
Number of subjects: 507
Study 33118055 — intervention group
Group type: EXPERIMENTAL
Intervention: High nicotine concentration (15.8 mg/g)
Number of subjects: 360
Study 33118055 — intervention group
Group type: COMPARATOR
Intervention: Moderate nicotine concentration (5.2 mg/g)
Number of subjects: 360
Study 33118055 — intervention group
Group type: COMPARATOR
Intervention: Low nicotine concentration (0.4 mg/g)
Number of subjects: 360
Study 35068061 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg twice daily + tamsulosin 0.4 mg once daily
Number of subjects: 63
Study 35068061 — intervention group
Group type: COMPARATOR
Intervention: Placebo + tamsulosin 0.4 mg once daily
Number of subjects: 63